Ear Apex blood-letting random control study on treatment of stye

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002201

Enrollment

Unknown

Registered

2012-05-28

Start date

2011-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

External hordeolum

Interventions

Bloodletting in Apex Group:Bloodletting in Apex +Conventional therapy

Conventional therapy group:Conventional drug therapy

Eligibility

Sex/Gender

All

Age

6 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. meets the diagnostic criteria of Western medicine and TCM syndrome differentiation and diagnosis for external hordeolum patients; 2. age: 6~65years old; 3. cooperation volunteers were selected, and signed informed consent, agree to adhere to treatment without interruption in the middle.

Exclusion criteria

Exclusion criteria: (1) Age: 6 years of age or over 65 years of age; (2) the body lower the resistance; (3) oral hormones, antibiotics and immunosuppressants (4) coagulation disorders; (5) ear abscess disease; (6) history of drug allergy patients; (7) pregnant or lactating women during the study period, pregnant women; (8) in patients with poor compliance.

Design outcomes

Primary

Measure	Time frame
Maximum diameter of masses;VAS;Disease outcome;	—

Countries

China

Contacts

Public ContactXueyi Chen

tsamlw@126.com+86 13565923367

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026